肠道微生物产生的代谢物及脂质成分血清水平与肝硬化患者慢加急性肝衰竭和死亡独立相关
在北美12个中心纳入602例住院肝硬化患者,采用液相色谱分析入院时血清代谢组,发现微生物来源的芳香化合物、次级或硫酸化胆汁酸、苯甲酸及雌激素代谢物升高、磷脂降低与慢加急性肝衰竭(ACLF)发生及住院和30天死亡相关,随机森林模型预测ACLF的AUC为0.84。
要点
- 微生物来源代谢物和脂质成分与肝硬化患者ACLF发生及住院、30天死亡独立相关。
- 特定微生物代谢物预测ACLF的AUC为0.84,预测住院死亡的AUC为0.81,预测30天死亡的AUC为0.77。
- 这些代谢物在临床参数基础上可显著增加对上述结局的预测能力。
核心结论
- 在控制临床特征后,微生物来源代谢物及脂质成分与肝硬化患者ACLF发生及住院或30天内死亡相关。
研究设计与样本
- 多中心代谢组学研究,纳入2015年至2017年北美12个三级肝病中心602例住院肝硬化患者,入院时采集血清。
- 采用液相色谱进行代谢组分析,并进行协方差分析、随机森林分析和AUC分析。
- 同时分析133例患者同期采集的粪便微生物组与血清代谢物的关联。
主要发现
- 602例患者中88例(15%)发生ACLF,43例(7%)住院期间死亡,72例(12%)30天内死亡。
- 微生物来源化合物(芳香化合物、次级或硫酸化胆汁酸、苯甲酸)和雌激素代谢物水平升高、磷脂水平降低与ACLF发生、住院死亡和30天死亡相关,也与粪便微生物组相关。
- 随机森林分析和逻辑回归显示,特定微生物代谢物预测ACLF的AUC为0.84(95%CI 0.78-0.88;P=0.001),预测住院死亡的AUC为0.81(95%CI 0.74-0.85;P=0.002),预测30天死亡的AUC为0.77(95%CI 0.73-0.81;P=0.02)。
- 这些代谢物对上述结局的预测在临床参数基础上具有显著附加价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inpatients with cirrhosis have high rates of acute-on-chronic failure (ACLF) development and high mortality within 30 days of admission to the hospital. Better biomarkers are needed to predict these outcomes. We performed metabolomic analyses of serum samples from patients with cirrhosis at multiple centers to determine whether metabolite profiles might identify patients at high risk for ACLF and death. METHODS: We performed metabolomic analyses, using liquid chromatography, of serum samples collected at time of admission to 12 North American tertiary hepatology centers from 602 patients in the North American Consortium for the Study of End-Stage Liver Disease sites from 2015 through 2017 (mean age, 56 years; 61% men; mean model for end-stage liver disease score, 19.5). We performed analysis of covariance, adjusted for model for end-stage liver disease at time of hospital admission, serum levels of albumin and sodium, and white blood cell count, to identify metabolites that differed between patients who did vs did not develop ACLF and patients who did vs did not die during hospitalization and within 30 days. We performed random forest analysis to identify specific metabolite(s) that were associated with outcomes and area under the curve (AUC) analyses to analyze them in context of clinical parameters. We analyzed microbiomes of stool samples collected from 133 patients collected at the same time and examined associations with serum metabolites. RESULTS: Of the 602 patients analyzed, 88 developed ACLF (15%), 43 died in the hospital (7%), and 72 died within 30 days (12%). Increased levels of compounds of microbial origin (aromatic compounds, secondary or sulfated bile acids, and benzoate) and estrogen metabolites, as well as decreased levels of phospholipids, were associated with development of ACLF, inpatient, and 30-day mortality and were also associated with fecal microbiomes. Random forest analysis and logistic regression showed that levels of specific microbially produced metabolites identified patients who developed ACLF with an AUC of 0.84 (95% confidence interval [CI] 0.78-0.88; P = .001), patients who died while in the hospital with an AUC of 0.81 (95% CI 0.74-0.85; P = .002), and patients who died within 30 days with an AUC of 0.77 (95% CI 0.73-0.81; P = .02). The metabolites were significantly additive to clinical parameters for predicting these outcomes. Metabolites associated with outcomes were also correlated with microbiomes of stool samples. CONCLUSIONS: In an analysis of serum metabolites and fecal microbiomes of patients hospitalized with cirrhosis at multiple centers, we associated metabolites of microbial origin and lipid moieties with development of ACLF and death as an inpatient or within 30 days, after controlling for clinical features.
引用
- Bajaj JS, Reddy KR, O'Leary JG, et al. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology. 2020. PMID: 32687928. doi:10.1053/j.gastro.2020.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。